RecruitingNot ApplicableNCT03562741

Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile


Sponsor

Krunal Patel

Enrollment

500 participants

Start Date

Jan 16, 2014

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to see if stool transplant performed by colonoscopy is effective at treating recurrent Clostridium difficile (C. diff) infection of the colon. During the procedure a stool sample is taken from a healthy donor (usually family member or close friend) and transplanted directly into the colon of the patient with C. diff infection. The goal of this experimental procedure (called fecal microbiota transplantation) is to replenish the good bacteria in the colon that can help prevent C. diff infection from coming back after treatment.


Eligibility

Min Age: 16 Years

Inclusion Criteria3

  • Two or more recurrences of C. difficile infection (CDI) with recurrence defined as a positive test result, e.g. Polymerase Chain Reaction (PCR) test and with appropriate symptoms within 2-8 weeks of last positive result, provided that symptoms from earlier episode resolved with or without therapy.
  • Failed standard therapy with oral metronidazole and/or oral vancomycin
  • One or more episodes of severe CDI resulting in hospitalization and not responding to standard antibiotic therapy. Hospitalization for CDI occurs in the setting of severe diarrhea, abdominal pain and signs of systemic toxicity

Exclusion Criteria2

  • Age \<16 years old
  • patients with acute severe colonic dilation at risk for colonic perforation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREFecal Microbiota Transplantation

Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation


Locations(1)

UMass Memorial Medical Center

Worcester, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03562741


Related Trials